Class summary at a glance.

Every drug in the Dietary Cholesterol Absorption Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $322.7Mcombined across class
Total Rx claims: 13.9M4.9M unique beneficiaries
Generic mfrs (active): 12across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ezetimibe

Brand: Zetia · 13.9M Part D claims (CY24) · 4.9M beneficiaries · First FDA approval: 2017-06-12

12 generic mfrs 0 plans require PA Discontinued

Low NADAC$0.073

→

Avg plan cost$0.438

Part D spend $322.7M 6× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.